Cortellis Deals Intelligence
Negotiate your best deal with pharma deals intelligence and analytics
Make smarter pharma deals with comprehensive data and insights
Evaluate life sciences biopharma deals to identify ideal partners, benchmark valuations, and empower negotiations. Assess comparable deal terms, conduct due diligence, and forecast success with predictive pharma deals insights.
Comprehensive pharma deals data with AI-powered analytics
Leverage early pipeline intel
Never miss emerging competitors or pharma licensing opportunities with comprehensive coverage of early-phase assets and the start-up companies behind them.
Predict deal outcomes with AI
Forecast biopharma deal values and success with our first-in-class, proven prediction tool – tailored by indication, company, phase, and deal type AC ALT.
Biopharma deal trends
Visualize deal activity, trends, and insights by therapy area in minutes to streamline due diligence and support stakeholder discussions.
Power a smarter deals strategy that maximizes ROI and competitive advantage
Confidently assess comparable deal terms and perform due diligence with comprehensive pharma deals intelligence
Find your ideal partner
Identify in-license opportunities based on your ideal candidate’s characteristics or identify potential pharma out-licensing partners based on experience in the field and/or portfolio gaps. Further explore potential partners’ deal history including payment terms.
Benchmark asset values and prepare for negotiations
Find comparable deals in a few clicks, and access complete contracts, including unredacted versions, to better understand your potential partner’s past deal terms. Create and export your own custom analyses and financial summaries to rapidly understand deal values.
Accurately forecast asset value
Predict potential deal sizes at each stage of drug development using our first-in-class AI-based deal value predictive analytics, and uncover how likely it would be for a drug to progress to the next phase of development if you were to partner.
Make high-value pharma deals intelligence faster
Confidently assess comparable pharma deal terms, evaluate financials and perform due diligence with a comprehensive pharma deals intelligence database.
Identify the best time to partner
Determine the optimal time to partner an asset based on a comprehensive and accurate understanding of the competition, existing pharma deals, and reliable forecasting.
Negotiate the most lucrative deal
Explore granular deal size and payment terms by phase/stage of development within deal reports and contracts.
Perform due diligence within minutes
Save hours of time by exploring aggregated, top pharma and multiyear deal trends by therapy area or indication.
Our offering in numbers
135k+
37k+
15.5k+
10k+
Resources
Pharma is placing bigger bets on fewer, more strategic assets/platforms
Looming patent cliffs drove the highest recorded deal values in 2024, as pharmas continued a strategic shift towards making fewer but higher-stakes transactions. However, geopolitical uncertainty has put a damper on investment.
Emerging Deal Making Trends in Biotech and Pharma
Biotech companies face numerous challenges when partnering with big pharma, including validating innovations, navigating regulatory pathways, addressing financial considerations, aligning strategies, protecting intellectual property, demonstrating capabilities, and proving market potential. Overcoming these challenges requires careful planning, strong communication, and strategic thinking to create mutually beneficial partnerships. Watch our on-demand webinar to explore 2024 deal-making trends...
Increasing your likelihood of success in dealmaking discussions
In-licensing and acquisitions are fast tracks for pharmaceutical companies to access groundbreaking technologies and assets that will drive the next generation of transformative patient treatments. Dealmaking is not a trivial…
Frequently asked questions about pharma deals intelligence
Cortellis Deals Intelligence is a biopharma deals intelligence platform that helps life sciences companies evaluate, negotiate, and execute successful partnering, licensing, and M&A transactions with confidence.
The platform delivers comprehensive insight into biopharma partnerships and M&A activity, with robust global coverage across deal types (including early‑stage deals), deal terms, contracts, assets, and company profiles. This depth enables teams to conduct informed deal analysis and negotiate stronger outcomes across the deal lifecycle.
The platform also includes 15,500+ deals with contracts, including unredacted agreements, providing transparency into deal structures, terms, and deal economics across global pharma markets.
Whether supporting in‑licensing, out‑licensing, or M&A strategy, Cortellis Deals Intelligence delivers actionable biopharma deal intelligence to help organizations optimize deal decisions, manage risk, and maximize return on investment.
Cortellis Deals Intelligence is essential for business development and licensing teams across biotech, specialty pharma, and large pharma companies.
Primary users include business development professionals responsible for partner identification and deal negotiation, licensing specialists benchmarking deal terms and valuations, and corporate development executives managing M&A and partnership strategy. The platform serves companies at all stages — from emerging biotechs evaluating out-licensing partners to large pharmaceutical organizations conducting strategic acquisitions and determining optimal partnership timing.
Across roles and company sizes, biopharma professionals rely on Cortellis Deals Intelligence to confidently make informed, high-value deal decisions while reducing the time and effort required to gather intelligence from multiple sources.
Leading pharmaceutical and biotech companies choose Cortellis Deals Intelligence because it is a purpose‑built biopharma deal intelligence database that combines comprehensive pharmaceutical licensing and M&A data with predictive analytics designed specifically for life sciences dealmakers.
What sets Cortellis Deals Intelligence apart:
- Broad and deep biopharma deals data: Access a robust global dataset covering licensing, partnering, and M&A transactions — including unredacted agreements and detailed financial terms, and strong early-stage deal coverage.
- First‑in‑class advanced predictive deal analytics: Leverage Deals Predictive Analytics, trained on thousands of real-world pharma deals, to help assess deal success probabilities, reduce the risk of under‑ or over‑valuation, and improve deal strategy earlier in the process.
- Actionable intelligence for confident negotiations: Combines historical deal comparables and predictive insights to enable teams to negotiate from a position of strength and support data‑driven decision‑making across BD&L, strategy, and corporate development activities.
When your organization is making high‑stakes, million‑dollar biopharma deal decisions, industry-leading data quality and proven predictive analytics help reduce risk, improve deal outcomes, and maximize ROI.
Cortellis Deals Intelligence supports data‑driven decision‑making across the full biopharma deal lifecycle, from early strategy to execution and negotiation. Teams use it to:
- Identify optimal partnership timing based on market activity, deal trends, and asset maturity
- Evaluate and shortlist potential partners using comparable deal activity, strategic fit, and partner deal history
- Assess and benchmark assets with historical deal comparables, financial terms, unredacted contracts, and proven predictive deal insights
- Support M&A strategy and due diligence with access to unredacted agreements, financial summaries, and multi-year deal activity insights
- Prepare for negotiations using robust benchmarks, deal precedents, and valuation context
By grounding each decision in comprehensive biopharma deal data and predictive analytics, Cortellis Deals Intelligence enables more confident, defensible outcomes for business development, licensing, corporate development, and strategy teams.
Yes, Cortellis Deals Intelligence data can be delivered as bulk data via feeds or APIs so you can power internal analytics, dashboards and enterprise applications with trusted biopharma deals intelligence.
Follow us
Contact us
